Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumor and causes
90% of skin cancer mortality. A unique collaboration of multi-disciplinary experts from the …

BACKGROUND Immunotherapies that target the interaction of programmed death 1 (PD-1)
with its ligands, PD-L1 and PD-L2, have ushered in the modern oncology era. The PD-1 …

Background Pembrolizumab prolongs progression-free and overall survival among patients
with advanced melanoma and recurrence-free survival in resected stage III disease …

Relatlimab and nivolumab combination immunotherapy improves progression-free survival
over nivolumab monotherapy in patients with unresectable advanced melanoma. We …

Patients with resected stage IIB/C melanoma have high recurrence risk, similar to those with
resected stage IIIA/B disease. The phase 3, double-blind CheckMate 76K trial assessed 790 …

Summary Background The European Organisation for Research and Treatment of Cancer
(EORTC) 1325/KEYNOTE-054 trial assessed pembrolizumab versus placebo in patients …

Over the past few years, the NCCN Guidelines for Melanoma: Cutaneous have been
expanded to include pathways for treatment of microscopic satellitosis (added in v2. 2020) …

Cutaneous melanoma remains the most lethal of the primary cutaneous neoplasms, and
although the incidence of primary melanoma continues to rise, the mortality from metastatic …

This ESMO Clinical Practice Guidelines provide updated recommendations on management
of cutaneous melanoma (diagnosis, treatment and follow-up), compiled by a …

PURPOSE We conducted the phase III double-blind European Organisation for Research
and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial to evaluate pembrolizumab …